Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Revenue of Mind Medicine (MindMed) Inc. (MNMD)
Revenue in 2023 (TTM): $
According to Mind Medicine (MindMed) Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Mind Medicine (MindMed) Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-3,162,000 | $-92,570,000 | $-95,732,000 | $-95,732,000 |
| 2022 | $ | $-3,223,000 | $-53,573,000 | $-56,796,000 | $-47,261,000 |
| 2021 | $ | $-2,616,000 | $-91,218,000 | $-94,193,000 | $-93,036,000 |
| 2020 | $ | $ | $-33,773,000 | $-33,937,000 | $-34,101,000 |
| 2019 | $ | $-6,684 | $-1,109,122 | $-1,115,806 | $-1,115,806 |
| 2018 | $ | $-6,682 | $-851,262 | $-857,944 | $-857,944 |
| 2017 | $ | $-5,501 | $-1,507,962 | $-1,226,733 | $-1,226,733 |
| 2016 | $ | $ | $-111,250 | $-179,900 | $-179,900 |
| 2015 | $ | $ | $-92,656 | $-92,656 | $-92,656 |